0
Zum Inhalt springen
Dein Website-Titel
Terms & Conditions
Privacy Policy
Dein Website-Titel
Terms & Conditions
Privacy Policy
Terms & Conditions
Privacy Policy

WHO WE ARE

GANYMED was founded by internationally renowned medical experts in the field of therapeutic apheresis. With over 40 years of combined clinical experience in internal medicine and apheresis, our team has developed and clinically validated innovative technologies and treatment protocols targeting hard-to-treat chronic diseases. Through extracorporeal blood and plasma processing, we remove unwanted environmental contaminants—such as heavy metals and microplastics—as well as harmful biomolecules, including autoantibodies, lipids, and endotoxins, which are recognized as key contributors to chronic disease.

WHAT WE DO

  • GANYMED provides clinical expertise and proprietary, state-of-the-art apheresis solutions to treat chronic diseases where the removal of harmful substances from the blood offers a potentially curative approach. Our protocols currently focus on preventing and managing cardiovascular diseases (e.g., atherosclerosis, heart attacks) and neurodegenerative conditions (e.g., Alzheimer’s disease). We also target complex, hard-to-treat conditions such as Long COVID, autoimmune diseases, and environmental toxin burdens caused by elevated levels of heavy metals and microplastics.

  • Based in Dubai (UAE), GANYMED collaborates with healthcare institutions to make its advanced therapies accessible to patients in the region. We offer comprehensive support, including treatment protocols, training, and medical consulting through our network of international experts. In addition, we provide sophisticated laboratory diagnostics for monitoring treatment success. All proprietary medical devices and consumables are imported and made available locally to ensure seamless implementation.

  • Beyond strategic partnerships, GANYMED plans to operate its own dedicated apheresis centers in the UAE. These centers will offer direct access to our innovative treatments and serve as clinical hubs for excellence in therapeutic apheresis.

Continuous Clinical Evaluation

To ensure optimal treatment outcomes, GANYMED continuously collects and analyzes anonymized clinical data from all affiliated centers. This benchmarking process enables the comparison of treatment performance across sites and supports ongoing refinement of protocols.

Scientific Collaboration and Knowledge Sharing

GANYMED promotes collaborative research and joint scientific publications with its partner institutions. By contributing to peer-reviewed journals, GANYMED advances the field of therapeutic apheresis and shares valuable clinical insights with the global medical community.

Outcome Monitoring and Digital Tools

Participating centers receive standardized tools such as electronic Case Report Forms (eCRFs) and structured questionnaires. These instruments facilitate regular (quarterly) assessment of clinical outcomes and help maintain high standards of care across the network.

GLOSSARY

  • Apheresis (from Greek ἀφαίρεσις [aphairesis], meaning “a taking away”) is a medical procedure in which a person’s blood is passed through an apparatus that separates out specific components and returns the remainder to the circulation. It is considered an extracorporeal therapy, meaning the treatment occurs outside the body.

  • Apheresis techniques are used when specific blood components contribute to disease symptoms. The procedure is typically repeated regularly and is invasive, so it is usually reserved for cases where conventional treatments have failed or where immediate intervention is necessary to prevent complications or relieve severe symptoms.

    In autoimmune diseases, apheresis is not used as a standalone therapy but in combination with treatments that reduce the production of autoantibodies.

    • Plasma Exchange (Plasmapheresis): Removes the liquid portion of the blood (plasma) to eliminate harmful substances. The plasma is then replaced with a suitable substitute.

    • LDL Apheresis: Selectively removes low-density lipoprotein (LDL) cholesterol in patients with familial hypercholesterolemia.

    • Lipoprotein(a) [Lp(a)] Apheresis: Targets and removes elevated Lp(a), a cardiovascular risk factor.

    • Photopheresis: Used primarily for treating graft-versus-host disease, cutaneous T-cell lymphoma, and organ transplant rejection. It involves treating white blood cells with ultraviolet light before reinfusing them.

    • Immunoadsorption with Protein A-Agarose Columns: Used to remove allo- and autoantibodies in conditions such as autoimmune diseases, transplant rejection, and hemophilia. The plasma is passed through columns containing Staphylococcal Protein A, a molecule that binds the Fc region of immunoglobulin G (IgG).

Let Us Stay In Contact

Sign up with your email address to receive more information

Thank you!

 
Terms & Conditions
Privacy Policy